The cost-utility of neoadjuvant treatment with the use of trastuzumab plus pertuzumab or lapatinib, another monoclonal antibody, compared to single therapy with trastuzumab and chemotherapy was analysed [37] from the perspective of five-year budget impacts regarding the population of patients with HER2+ breast cancer. This evidence concerns the gene ERBB2 and breast cancer.